Moderna Stock Selloff: Why positive cancer vaccine results failed to lift shares

Moderna shares plunged after detailed cancer vaccine trial results triggered profit-taking despite reducing melanoma recurrence risk by 42%. Investors weigh commercial prospects, regulatory timelines, and future oncology opportunities.

Khabar Adda curates headlines like this across Top Stories, Entertainment, Bollywood, Hollywood, Crime and Politics from public RSS feeds. This page links out to economictimes.indiatimes.com's own reporting rather than reproducing it — the excerpt above comes from economictimes.indiatimes.com's own feed.